74 compound-focused publications · 16 studies with detailed explanations.
Click a paper title or Read summary to open its reading page. Find a detailed explanation or a short, attributed abstract excerpt, then follow the original source for the full conclusion.
74 of 74 publications · Showing 1–30
Wise J · BMJ (Clinical research ed.)
Why included: The compound is a named subject of the publication title.
Journal Article · No abstract indexed
Jastreboff AM, Kaplan LM, Davies MJ et al. · The New England journal of medicine
Why included: The compound is a named subject of the publication title.
Journal Article
Bellido V, le Roux CW, Ekinci EI et al. · Lancet (London, England)
Why included: The compound is a named subject of the publication title.
Journal Article
Kaczynski MM, Zureikat RM, Kaczynski MR et al. · Biomedicines
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Yovera-Aldana M, Manrique-Hurtado H, Umpierrez GE · JCEM case reports
Why included: A Prader-Willi syndrome case describes sequential treatment including retatrutide; outcomes cannot be assigned solely to this drug.
Case Reports · Journal Article
Petersen J, Merrild C, Holm SK et al. · Nature metabolism
Why included: The compound is a named subject of the publication title.
Journal Article
Chen D, Ma B, Sun H et al. · BMJ medicine
Why included: A network meta-analysis includes retatrutide trial estimates for weight loss and treatment discontinuation.
Journal Article
Branine N · Cureus
Why included: The compound is a named subject of the publication title.
Case Reports · Journal Article
Ding M, Li X, Wei Y et al. · iScience
Why included: The compound is a named subject of the publication title.
Journal Article
Ruotolo G, Harris C, Lin Y et al. · Diabetes, obesity & metabolism
Why included: The compound is a named subject of the publication title.
Journal Article
Tong LH, Leung KK, Hung CT · Journal of chromatography. A
Why included: An LC-HRMS analytical method explicitly includes retatrutide quantitation; it does not assess clinical effectiveness.
Journal Article
Brown C · BMJ (Clinical research ed.)
Why included: The compound is a named subject of the publication title.
Journal Article · No abstract indexed
Piatkowski T, Craven A, Cornell S et al. · Drug and alcohol review
Why included: Laboratory analysis measured identity, content and metals in three products sold as retatrutide; this is preparation-specific analysis, not a clinical efficacy study. PubMed provides no abstract.
Letter · No abstract indexed
Ferreira J · Lab animal
Why included: The compound is a named subject of the publication title.
Journal Article · No abstract indexed
Mahase E · BMJ (Clinical research ed.)
Why included: The compound is a named subject of the publication title.
Journal Article · No abstract indexed
Keskin U, Altın E, Kara MK et al. · Behavioural brain research
Why included: The compound is a named subject of the publication title.
Journal Article
Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V · High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
Why included: The compound is a named subject of the publication title.
Journal Article · Meta-Analysis · Systematic Review
Lang K · BMJ (Clinical research ed.)
Why included: The compound is a named subject of the publication title.
Journal Article · No abstract indexed
Bajaj HS, Welch M, Shah P et al. · Lancet (London, England)
Why included: The compound is a named subject of the publication title.
Journal Article · Randomized Controlled Trial · Clinical Trial, Phase III · Multicenter Study · Research Support, Non-U.S. Gov't
Mao CY, Pang ZJ, Qiao GY et al. · Organic letters
Why included: The compound is a named subject of the publication title.
Journal Article
Takahashi M, Abe I, Yoshida N et al. · Nature communications
Why included: The atrial-fibrillation research used LY3437943 (retatrutide) as an experimental weight-loss intervention.
Journal Article
Pearson MJ, Willency JA, Lin Y et al. · The Journal of clinical endocrinology and metabolism
Why included: The compound is a named subject of the publication title.
Journal Article
Pillai AA, Godin SL, Frishman WH et al. · Cardiology in review
Why included: The compound is a named subject of the publication title.
Journal Article
Perez-Tilve D, Zhang F, Zhang Y et al. · Molecular metabolism
Why included: Retatrutide was experimentally compared in mice lacking GLP-1 receptors.
Journal Article
Li Q, Cheng W, Zhang J et al. · Diabetology & metabolic syndrome
Why included: The compound is a named subject of the publication title.
Journal Article
Panou T, Gouveri E, Popovic DS et al. · Expert review of clinical pharmacology
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Briand F, Le Cudennec C, Grasset E et al. · Obesity (Silver Spring, Md.)
Why included: The compound is a named subject of the publication title.
Journal Article
Hitaka K, Sugawara T, Matsumoto M et al. · International journal of obesity (2005)
Why included: The compound is a named subject of the publication title.
Journal Article · Comparative Study
Ganamurali N, Sabarathinam S · Clinical pharmacology in drug development
Why included: The compound is a named subject of the publication title.
Journal Article · Review
Heerspink HJL, van Raalte DH, Bjornstad P et al. · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Why included: The compound is a named subject of the publication title.
Journal Article · Clinical Trial Protocol
Glucose and weight improved relative to placebo, with gastrointestinal events most frequent. The population, follow-up, and investigational formulation limit application beyond this trial.
This trial studied a controlled investigational formulation and selected adults with type 2 diabetes. It does not establish every long-term outcome or the identity and safety of retail research products.
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Bajaj HS et al. · Lancet (London, England) · 2026
Why included: The compound is a named subject of the publication title.
Read the original study PMID 42250575 · PubMedOpen study summaryThe tissue showed contraction responses under laboratory conditions. Human-derived tissue does not make this a trial of heart function, cardiovascular benefit, or safety in patients.
Patient-derived tissue outside the body remains laboratory evidence. This does not establish cardiac benefit, arrhythmia risk, or clinical safety in people.
Inotropic effects of retatrutide in isolated human atrial preparations.
Neumann J et al. · Naunyn-Schmiedeberg's archives of pharmacology · 2026
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40613938 · PubMedOpen study summaryRetatrutide altered an experimental alcohol cue. That result does not establish reduced drinking or treatment of alcohol-use disorder in people, and the repeated semaglutide findings should not be assigned to retatrutide.
A rat discrimination task does not establish reduced drinking or treatment of alcohol use disorder in humans. The three drugs should not be treated as interchangeable.
Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.
Windram M et al. · Psychopharmacology · 2026
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40699363 · PubMedOpen study summaryThe analysis used a subset of the parent trial with available scans. Weight loss included lean mass loss; this is not an independent trial or proof that muscle is preserved.
This shares the parent diabetes-trial population. Only 103 participants completed treatment and both DXA scans, limiting interpretation; it does not demonstrate muscle preservation or retail-product safety.
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Coskun T et al. · The lancet. Diabetes & endocrinology · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40609566 · PubMedOpen study summaryThe intervention findings were reported in female mice. Similarities between mouse and human gene patterns do not establish a clinical effect on liver inflammation or scarring.
The accelerated mouse model does not establish treatment of human liver disease.
Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.
Viebahn GK et al. · American journal of physiology. Gastrointestinal and liver physiology · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 41056349 · PubMedOpen study summaryProtein and lipid changes occurred together, while cell experiments suggested a glucagon-receptor mechanism. The clinical correlations do not alone prove that this mechanism caused the lipid changes.
These are secondary analyses of existing trials, not additional independent trials. Associations and cell experiments cannot prove clinical cardiovascular benefit.
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
Wen Y et al. · Diabetes, obesity & metabolism · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40726454 · PubMedOpen study summaryThe interviews provide detail about experience, including adverse effects and unmet expectations. Uneven groups and selected interviewees limit treatment comparisons and generalization.
Qualitative interviews from a selected trial subset are not a separate efficacy trial or an unbiased estimate of how often experiences occur.
Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.
Goetz IA et al. · Obesity pillars · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 41216380 · PubMedOpen study summaryTumor findings in these experimental models do not demonstrate cancer prevention or treatment in people. The study's clinical possibilities remain hypotheses.
Mouse tumor experiments do not establish cancer prevention or treatment in people.
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.
Marathe SJ et al. · npj metabolic health and disease · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40094000 · PubMedOpen study summaryQuestionnaire changes concern perceptions and behaviors reported during an existing trial. Correlation with weight loss does not show which change caused the other.
Self-reported secondary endpoints come from an existing trial and do not independently establish the mechanism of weight loss.
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
Kanu C et al. · Diabetes, obesity & metabolism · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40916752 · PubMedOpen study summaryThe tested left atria did not show increased force, while right-atrial beating rate increased through a proposed glucagon-receptor pathway. This is not a whole-animal or human cardiac-outcomes study.
Isolated mouse heart tissue cannot establish human rhythm risk or cardiovascular safety.
Contractile effects of retatrutide in isolated mouse atrial preparations.
Neumann J et al. · Naunyn-Schmiedeberg's archives of pharmacology · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40464942 · PubMedOpen study summaryMost participants had normal baseline urine albumin, so absolute changes were modest. Changes in estimated filtration or urine markers do not establish prevention of kidney failure.
Most participants had normal baseline albumin excretion. These secondary analyses are not independent kidney-outcome trials.
The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
Heerspink HJL et al. · Kidney international reports · 2025
Why included: The compound is a named subject of the publication title.
Read the original study PMID 40630318 · PubMedOpen study summaryLiver fat fell more in the retatrutide groups than with placebo. These are imaging outcomes from the parent trial's participants, not a separate confirmation of clinical liver benefit. Less liver fat does not by itself demonstrate less scarring or fewer liver-related complications.
This is a substudy of the obesity trial, not an independent replication. Liver-fat imaging does not establish effects on fibrosis, clinical liver outcomes, or long-term safety.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Sanyal AJ et al. · Nature medicine · 2024
Why included: The compound is a named subject of the publication title.
Read the original study PMID 38858523 · PubMedOpen study summaryWeight changes were group averages, not predictions for an individual. Gastrointestinal adverse events were common and generally mild to moderate. Dose-related heart-rate increases peaked at 24 weeks and then declined; weight change alone does not describe the safety findings.
This selected 2023 trial concerns a controlled investigational formulation and population. It does not validate a retail research vial or establish its safety.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
Jastreboff AM et al. · New England Journal of Medicine · 2023
Why included: The compound is a named subject of the publication title.
Read the original study PMID 37366315 · PubMedOpen study summaryGlucose and weight outcomes differed by study group, and gastrointestinal events were frequent. The controlled investigational product and selected population define the scope of these results.
This controlled phase 2 study used an investigational formulation and selected population. It does not establish long-term outcomes or the safety of retail research vials.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
Rosenstock J et al. · Lancet (London, England) · 2023
Why included: The compound is a named subject of the publication title.
Read the original study PMID 37385280 · PubMedOpen study summaryThe different experiments support a development hypothesis but answer different questions. Mouse energy-expenditure mechanisms and early human observations do not establish long-term clinical outcomes.
Discovery experiments and early human exposure do not establish long-term clinical benefit or retail-product equivalence.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Coskun T et al. · Cell metabolism · 2022
Why included: The compound is a named subject of the publication title.
Read the original study PMID 35985340 · PubMedOpen study summaryTwenty-nine participants discontinued early, and gastrointestinal problems were common. The short, small study was designed for early development rather than definitive efficacy or long-term safety.
A small early-phase trial with treatment discontinuations provides limited information about uncommon harms and long-term outcomes.
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Urva S et al. · Lancet (London, England) · 2022
Why included: The compound is a named subject of the publication title.
Read the original study PMID 36354040 · PubMedOpen study summary